TME Pharma


The documentations contained in this archive section are provided for historical purposes only. The information contained in each documentation is accurate only as of the date each documentation was originally issued. TME Pharma disavows any obligation to update the information contained in such documentations after the date of their issuance.

Presentations/Communications

2022, July - Corporate Presentation
2022, June 10 - KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma 
  - download the presentation
  - download transcript
  - view webinar recording
2022, June 05 – NOXXON presents full top-line results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 ASCO Annual Meeting
  - download poster
  - view video of ASCO 2022 poster presentation commented by Dr. Frank A. Giordano
2021, November 23 – KOL Webinar with Dr. Frank Giordano on NOX-A12 & Radiotherapy Combination in Brain Cancer incl. Data Presented at the SNO Annual Meeting
  - view presentation
  - view webinar recording
2021, November 19 – SNO Annual Meeting 2021 Presentation by Dr. Frank Giordano
  - view presentation
2020, September - ESMO Congress 2020 Poster Presentation
  -download poster
  -view presentation 
2019, September 30 - Webcast: ESMO Congress 2019 Poster Presentation
  -download poster
  -download presentation
2019, September 23 - Webinar: What’s next in treatment of brain cancer patients? Testing NOX-A12 with Radiotherapy in a Phase 1/2 Clinical Trial
  -download presentation
  -download draft script

Annual Reports

2022, April 22 - 2021 Annual Report
2021, April 28 - 2020 Annual Report
2020, April 22 - 2019 Annual Report (Corrected version: contains corrected date of  signature of the audit opinion, and no other changes.)
2020, April 22 - 2019 Annual Report
2019, April 12 - 2018 Annual Report
2018, April 30 - 2017 Annual Report
2017, June 07 - 2016 Annual Report - statutory
2017, April 30 - 2016 Annual Report - non statutory

2016, December 07 - 2015 NOXXON Pharma N.V. IFRS

Prospectus/Information Documents

2017, July 11 - NOXXON Pharma NV Prospectus approved 10 July 2017 (English with summary of prospectus in French)
2016, September 28 - Information Document

Managers Transactions (as disclosed by company to competent authority)

2022, July - Transactions related to grant of stock options to Aram Mangasarian, Bryan Jennings
2022, July -Transactions related share purchases 8 July 2022: Aram Mangasarian
2022, July - Transactions related to cancelation of stock options to Aram Mangasarian, Bryan Jennings
2022, June/July - Transactions related share purchases 30 June 2022 and 1 July 2022: Aram Mangasarian 
2022, June 29 - Transactions related to grant of stock options to Martine J. van VugtSusan ColesOscar IzeboudGregory Weaver
2021, November 01 - Transactions related to grant of stock options to William Bryan Jennings
2021, June 24 - Transactions related to grant of stock options to Aram MangasarianMartine J. van VugtSusan ColesGregory Weaver
2020, June 30 - Transactions related to grant of stock options to Aram MangasarianOscar Izeboud
2020, April - Sale of shares effective 17 April 2020, Donald deBethizy
2019, October 09 - Transactions related to grant of stock options to Aram Mangasarian, Donald deBethizy
2019, August - Transaction related to Aug 2019 private placement, share purchases effective 15 Aug 2019: Aram Mangasarian
2019, July - Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Donald deBethizy (second)
2019, July - Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Aram Mangasarian
2019, July - Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Donald deBethizy (first)

Financing Instruments

Overview and Characteristics of the Convertible Bonds of the financing agreement published on April 23, 2020
as amended on October 14, 2020
2022, September 14 - Overview of the Convertible Bonds
2022, January 03 - Press release
2020, October 14 - Characteristics of the Convertible Bonds as amended 
2020, October 14 - Press release
2020, April 23 - Characteristics of the Convertible Bonds 
2020, April 23 - Press release

Terms of the Warrants of the financing agreement signed on November 15, 2018
2020, April 17 - Overview of the Warrants
2018, November 16 - Terms of the Warrants
2018, November 16 - Press release

Overview and Characteristics of the Convertible Notes listed on Euronext Access Paris in Sept 2018
2018, December 11 - Overview of the Outstanding Notes Listed on Euronext Access Paris - NOXXON7%PT
2018, November 16 - Issuer conversion notices submitted on November 16, 2018
2018, September - Terms and Conditions
2018, September - Euronext Listing Announcement
2018, November 16 - Press release
2018, September 19 - Press release

Overview and Characteristics of the Notes and Warrants of the financing agreement signed on May 01, 2017
2022, June 02 - Updated Summary Table of ODIRNANE & BSA
2017, May 02 - Characteristics of the Warrants
2017, May 02 - Characteristics of the Notes

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.